On July 25, 2025, the School of Pharmacy at Peking University and Beijing Genecradle Therapeutics Technology Co., Ltd. signed a joint research agreement at the National Key Laboratory of Natural and Biomimetic Drugs, focusing on the development of tRNA gene therapy drugs to forge new pathways for the treatment of rare diseases. This collaboration, witnessed by Professor Zhou Demin, Director of the National Key Laboratory of Natural and Biomimetic Drugs and Dean of Peking University Ningbo Institute of Marine Drugs, Professor Xia Qing and student representatives from the School of Pharmacy, Professor Wu Xiaobing, founder of Genecradle Therapeutics, and Ma Wenhao, head of the R&D center at Genecradle Therapeutics, marks the deep integration of Genecradle's industrial gene therapy capabilities and the School of Pharmacy's research strengths in nucleic acid drugs at Peking University.

At the signing ceremony, Director Zhou Demin systematically reviewed the School of Pharmacy's research foundation in the field of gene therapy and proposed the joint development of a new generation of tRNA drugs. Professor Xia Qing's team showcased their research achievements in tRNA drugs for the treatment of four rare diseases and engaged in in-depth discussions on key issues for clinical translation, such as patient selection and production quality control. Professor Wu Xiaobing shared her experience in gene therapy drug development and elaborated on the core advantages of adeno-associated virus (AAV) vectors as ideal delivery tools for gene therapy. She stated that Genecradle Therapeutics will leverage its strengths in AAV vector development to help Peking University's tRNA drugs make the leap from basic research to clinical application.

This collaboration integrates Peking University's academic accumulation in tRNA drug development with Genecradle Therapeutics' technical achievements in the AAV vector field, focusing on the development of innovative drugs in the rare disease field. Currently, Genecradle Therapeutics has established a pipeline of independently developed gene therapy drugs and advanced them to Phase I/II/III clinical trials, with several projects achieving significant progress in treating major rare diseases such as spinal muscular atrophy and Pompe disease, demonstrating strong translational potential. Through the industry-academia-research collaboration mechanism, both parties will accelerate the development of tRNA gene drugs, bringing new hope to more patients.